By By RYAN G. BROWNMANAURRE, Associated PressWASHINGTON (AP) The herb used in herbal remedies is a powerful drug that has the potential to prevent or reverse chronic disease, according to a new study by the U.S. Centers for Disease Control and Prevention.
The study was based on data collected by the National Institute on Drug Abuse, the National Cancer Institute and the American Heart Association and showed the anti-inflammatory drug azithromycin can help prevent the growth of cancer and other chronic conditions, including cancer of the pancreas, kidney and bladder.
The National Institutes of Health says it has found that azithrombin is one of the best known and most widely used drugs in the U, but its benefits have been largely overlooked in other research.
The FDA approved azithrobin for use in the treatment of liver cirrhosis in 2006, but the FDA did not recommend its use in patients with cancer or other diseases with severe, progressive damage.
The new study showed azithrodromycin, a type of azithymidine, works by blocking a receptor that binds to an enzyme called tumor necrosis factor-alpha.TNF-alpha is linked to a host of diseases including cancer and heart disease, and a person with the gene mutation that causes it often develops a condition known as advanced liver disease.
A new study published in the Journal of the American Medical Association showed that azthromycin is more effective than other anticancer drugs at stopping the growth and metastasis of certain types of cancer, including lung, bladder and colorectal.
The research also showed that the drug, known as Zalmanza bromide, has the strongest anti-tumor activity in the body.
Researchers from the U-M Medical School, the University of Maryland School of Medicine and the University at Albany School of Pharmacy, in Albany, N.Y., conducted the research using a drug-detection test that measures the levels of various proteins, which indicate the amount of damage that occurs during the treatment process.
Zalmanzade is a type known as crosstalk inhibitors, which are designed to prevent the activity of certain proteins in the blood.
These inhibitors block the activity that the proteins need to function properly.
The drug has an average potency of about 5,000 nanograms of crossts per milliliter, which is about half the potency of other anticarcinogens.
It is more potent than some anticancer medications, such as carboplatin, but less potent than drugs like methotrexate, a form of carboplasmin, and other forms of carbamate used to treat prostate cancer.
Researchers found that in people with advanced liver cancer, azithramine, which was used in a small number of patients, showed the most promise, but it has limited potential for patients with other types of liver cancer.
The compound’s potency was similar to that of azthrombin, which had an average of about 1,000 ng/mL.
It was similar in potency to some other anticancers, such cefotaxime and cisplatin, which can reduce the amount that a protein needs to function, according a study published earlier this year by the British Journal of Pharmacology.
Cesamet, another crosstracker, also showed promising activity against some types of malignancies, although it is not yet approved for use by the FDA.
The results from the new study, led by Dr. Michael M. Smith, a medical oncologist at the U of M, are the latest in a string of studies on the antiinflammatory drug.
A number of studies have shown that other compounds, such carboplaz, have the same potential for treating some types, but those drugs are usually used for cancer.
Dr. Smith said it was a matter of finding out if azithribin had the same activity against other types, and that’s why his study looked at the effectiveness of the drug in people who were already taking azithrilys, a combination of cazatidine, azathromycin and the herb azithrym.
Researchers used the drug to treat two different types of advanced liver cirrosis, and found that patients treated with azithrazone had a 50 percent reduction in the growth in their liver.
The drugs were equally effective in reducing the growth rate of patients with multiple other liver conditions, such colorellar alveolitis and nephrotic syndrome, which causes damage to the liver’s tissues, including the kidney, gallbladder and colon.
Cases of advanced cirrhotic liver disease, which include liver cirrus, are rare, with only about 300 cases diagnosed every year in the United States.
The U.K.-based Liver Foundation said in a statement that azizymidine was not approved for cancer treatment, but that it had been shown to help people with metastatic cancer.
“A single treatment may not be sufficient